Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNF-α and IL-1β expressions were significantly higher in the meningioma and glioma group in comparison to control group.
|
31653130 |
2019 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previously shown that tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell survival via binding to the Fn14 receptor, activation of the NF-kappaB pathway, and upregulation of BCL-X(L) gene expression.
|
19861406 |
2009 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ATM-NFκB axis-driven TIGAR regulates sensitivity of glioma cells to radiomimetics in the presence of TNFα.
|
23640457 |
2013 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Injection of IL-22 increased the severity of glioma <i>in vivo</i> and higher expression levels of IL-6, IL-1β and tumor necrosis factor (TNF)-α were detected in the brain using ELISA following IL-22 injection.
|
28450947 |
2017 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To elucidate the functional consequences of promoter methylation in the identified target death receptor 4 (DR4), we investigated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated and anti-DR4-mediated apoptosis in glioma cell lines (U373 and A172) with loss of DR4 and one glioma cell line (LN18) with robust DR4 expression.
|
19706813 |
2009 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies have shown that the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has significant apoptosis-inducing activity in some glioma cell lines, although many lines are either moderately or completely resistant, which has limited the therapeutic applicability of this agent.
|
21220502 |
2011 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell invasion via binding to fibroblast growth factor-inducible 14 (Fn14) and subsequent activation of the Rho guanosine triphosphatase family member Rac1.
|
23975833 |
2014 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To define novel pathways that regulate susceptibility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in glioma, we have performed genome-wide expression profiling of microRNAs (miRs).
|
22964638 |
2013 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
When the TNF-alpha gene was transfected into U251-SP cells, the expression of ICAM-1 was detected on the cell surface from 3 days after the transfection and continued until at least 9 days.
|
7915264 |
1994 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We show that in 3D CL matrix, interleukin-1 beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), cytokines which are elevated in gliomas in vivo, increased glioma cell invasiveness with correspondent elevation of MMP-2 and MMP-9.
|
18802741 |
2009 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-κB signaling.
|
25622756 |
2015 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sensitization of TNFalpha activated glioma cells to apoptosis by Ebselen involved 2 pathways: (i) abrogation of TNFalpha induced NF-kappaB activation and (ii) induction of Fas-associated death inducing signaling complex (DISC) formation.
|
18709644 |
2008 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we investigated the sensitivity of a panel of glioma cell lines (U87, U251, U343, U373, MZ-54, and MZ-18) to apoptosis induced by the death receptor ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL in combination with gamma irradiation, and TRAIL in combination with proteasome inhibitors (MG132 and epoxomicin).
|
18341587 |
2008 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor (TNF) superfamily, can stimulate glioma cell invasion and survival via binding to fibroblast growth factor-inducible 14 (Fn14) and subsequent activation of the transcription factor NF-κB.
|
28103571 |
2017 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results demonstrate that emodin could induce necroptosis in glioma possibly through the activation of the TNF-α/RIP1/RIP3 axis.
|
30924024 |
2020 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
While this work calls into question previous studies that have used the B-D13 antibody to assess IL13Rα2 expression, it also suggests that TNF may have significant effects on glioma biology by up-regulating VCAM-1.
|
24787244 |
2014 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression.
|
15611130 |
2005 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FAT10 expression is highly up-regulated by pro-inflammatory cytokines IFN-γ and TNF-α in all cell types and tissues and it was also found to be up-regulated in many cancer types such as glioma, colorectal, liver or gastric cancer.
|
27393295 |
2016 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
|
15844877 |
2002 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our therapeutic strategy was to use human bone marrow-derived mesenchymal stromal cells (hMSCs) as a cellular vehicle for the targeted delivery and local production of the biologic agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) at the glioma tumor site. hMSCs were transduced with a lentivirus expressing secretable TRAIL (S-TRAIL) and mCherry (red fluorescent protein).
|
19544410 |
2009 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This ability of CK2-Is to sensitize glioma to TNFα-induced death via multiple mechanisms involving abrogation of NF-κB activation, reactivation of wild-type p53 function and SIRT1 inhibition warrants investigation.
|
22318540 |
2012 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The combination effect was evaluated by the level of GFP and TNF expression in a human glioma cell line, and the mechanism of MMC effects on rAAV mediated gene expression was investigated by AAV transduction related signal molecules.
|
24451124 |
2013 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate the effectiveness of local IFNgamma and TNFalpha gene transfer as a treatment strategy for glioma and illustrate possible physiological pathways responsible for the therapeutic benefit observed.
|
12386831 |
2002 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both compounds exhibited selective cytotoxicity against human glioma stem cells (GSCs) and induced caspase-3 dependent extrinsic apoptosis by increasing the expression of interleukin 1 (IL-1), tumor necrosis factor (TNF-α), and the cleaved caspase-3, while damaged the unlimited proliferation and self-renewal capacity of GSCs.
|
29486949 |
2018 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we show that in contrast to other cancer types, tumor necrosis factor (TNF)-alpha suppresses YKL-40 expression in glioma cell lines in a nuclear factor kappaB (NF-kappaB) dependent manner.
|
18708058 |
2008 |